AbbVie Inc (ABBV)

pos +0.00
Today's Range: 61.87 - 62.79 | ABBV Avg Daily Volume: 12,531,700
Last Update: 04/17/15 - 4:01 PM EDT
Volume: 0
YTD Performance: -4.81%
Open: $0.00
Previous Close: $62.59
52 Week Range: $48.40 - $70.76
Oustanding Shares: 1,593,886,909
Market Cap: 99,652,397,423
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 7
Moderate Buy 0 0 0 0
Hold 2 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.40 1.60 1.73 1.73
Latest Dividend: 0.51
Latest Dividend Yield: 3.26%
Dividend Ex-Date: 04/13/15
Price Earnings Ratio: 56.90
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
56.90 56.80 27.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.49% 28.30% 0.00%
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
Revenue 19.96B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.84 $1.08 $4.32 $5.08
Number of Analysts 8 6 10 9
High Estimate $0.86 $1.11 $4.54 $5.45
Low Estimate $0.81 $1.03 $4.15 $4.51
Prior Year $0.72 $0.82 $3.32 $4.32
Growth Rate (Year over Year) 16.84% 31.91% 29.97% 17.63%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Apr 13, 2015 | 7:53 AM EDT
ABBV was upgraded from Market Perform to Outperform, BMO Capital said. Valuation call, based on a $68 price target.

Earnings Growth Boosts AbbVie Real Money Pro($)

Drug franchises are still going strong.
The ecstasy and the agony of M&A all in one day.
Combined Heinz-Kraft heads a long second-quarter list.
You can't help but feel better about both groups.
If there is no catalyst, I'd join those who sell on a bounce.
This sector could see some real damage.
Own them, or take something off the table?
Market backtracks on skepticism over biotechs.
It shouldn't be possible, but it never seems too late to get in.

Columnist Conversations

El Polo Loco Holding (LOCO) has been trading for less than a year and on the weekly timeframe many of the movi...
I am a proud new owner of an Apple Watch...sort of. While technically I own an Apple Watch Sport, it does not...
Last Thursday I gave a webinar talking about a rare price condition called the 'fat tail', and how option trad...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.